{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:02:16Z","timestamp":1790276536527,"version":"4.1.0"},"reference-count":50,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: To evaluate the effects of 10% GlicoPro tear substitute therapy in patients with severe dry eye disease (DED). Methods: In this prospective longitudinal study, 30 individuals receiving 10% GlicoPro four times daily for DED were evaluated. The ocular surface disease index (OSDI) questionnaire, average non-invasive break-up time (A-NIBUT), non-anesthetic and anesthetic corneal esthesiometry (CE), ocular pain, and the presence of conjunctivochalasis (CCH) were used as clinical endpoints. Treatment compliance using dosing diaries and AEs was assessed. Results: A significant improvement was observed in the clinical endpoints: the \u0394OSDI questionnaire was \u221239.27 \u00b1 13.22 [\u221265 to \u221215] points, \u0394A-NIBUT was 3.10 \u00b1 1.31 [1 to 5] s, \u0394non-anesthetic CE was 14 \u00b1 6.35 [5 to 25] mm, and \u0394anesthetic CE was 13 \u00b1 5.35 [5 to 20] mm (p &lt; 0.001 for all comparisons). Ocular pain was reduced in 92.5% of the patients at the end of the follow-up. However, there was no change in the presence of CCH. In addition, all the patients were fully compliant with the dosing and no AEs related to the use of the 10% GlicoPro tear substitute were reported. Conclusions: The 10% GlicoPro tear substitute has the potential to achieve beneficial effects in ocular surface treatments.<\/jats:p>","DOI":"10.3390\/jcm13061618","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T12:14:40Z","timestamp":1710245680000},"page":"1618","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluating GlicoPro Tear Substitute Derived from Helix aspersa Snail Mucus in Alleviating Severe Dry Eye Disease: A First-in-Human Study on Corneal Esthesiometry Recovery and Ocular Pain Relief"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-8685","authenticated-orcid":false,"given":"Antonio","family":"Ballesteros-S\u00e1nchez","sequence":"first","affiliation":[{"name":"Department of Physics of Condensed Matter, Optics Area, University of Seville, 41004 Seville, Spain"},{"name":"Department of Ophthalmology, Cl\u00ednica Novovisi\u00f3n, 30008 Murcia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-7717","authenticated-orcid":false,"given":"Jos\u00e9-Mar\u00eda","family":"S\u00e1nchez-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Department of Physics of Condensed Matter, Optics Area, University of Seville, 41004 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1350-3398","authenticated-orcid":false,"given":"Giovanni Roberto","family":"Tedesco","sequence":"additional","affiliation":[{"name":"Studio Oculistico Tedesco, 88025 Girifaldo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7464-2493","authenticated-orcid":false,"given":"Carlos","family":"Rocha-de-Lossada","sequence":"additional","affiliation":[{"name":"Qvision Ophthalmology Department, VITHAS Almeria Hospital, 04120 Almeria, Spain"},{"name":"Ophthalmology Department, VITHAS Malaga, 29016 Malaga, Spain"},{"name":"Regional University Hospital of Malaga, Hospital Civil Square, 29009 Malaga, Spain"},{"name":"Department of Surgery, Ophthalmology Area, University of Seville, 41009 Seville, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4053-7943","authenticated-orcid":false,"given":"Gianluca","family":"Murano","sequence":"additional","affiliation":[{"name":"Sacro Cuore\u2014iGreco Ospedali Riuniti, 87100 Cosenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spinelli","sequence":"additional","affiliation":[{"name":"Biomeeting, 89124 Reggio Calabria, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Mazzotta","sequence":"additional","affiliation":[{"name":"Siena Crosslinking Center, 53035 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6952-5647","authenticated-orcid":false,"given":"Davide","family":"Borroni","sequence":"additional","affiliation":[{"name":"Departament of Ophthalmology, Riga Stradins University, LV-1007 Riga, Latvia"},{"name":"Centro Oculistico Borroni, 21013 Gallarate, Italy"},{"name":"Eyemetagenomics Ltd., 71-75 Shelton Street, Covent Garden, London WC2 H9JK, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II Definition and Classification Report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s40135-013-0009-1","article-title":"Dry Eye Disease: Impact on Quality of Life and Vision","volume":"1","author":"Uchino","year":"2013","journal-title":"Curr. Ophthalmol. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jtos.2016.04.005","article-title":"Understanding Symptoms and Quality of Life in Patients with Dry Eye Syndrome","volume":"14","author":"Barabino","year":"2016","journal-title":"Ocul. Surf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II Diagnostic Methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jtos.2017.03.006","article-title":"TFOS DEWS II Tear Film Report","volume":"15","author":"Willcox","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II Management and Therapy Report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"DES151","DOI":"10.1167\/iovs.17-23623","article-title":"Secreted Mucins on the Ocular Surface","volume":"59","author":"Hori","year":"2018","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1097\/OPX.0000000000000664","article-title":"Altered Mucin and Glycoprotein Expression in Dry Eye Disease","volume":"92","author":"Stephens","year":"2015","journal-title":"Optom. Vis. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.preteyeres.2018.11.007","article-title":"Reconsidering the central role of mucins in dry eye and ocular surface diseases","volume":"71","author":"Baudouin","year":"2019","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Georgiev, G.A., Eftimov, P., and Yokoi, N. (2019). Contribution of Mucins towards the Physical Properties of the Tear Film: A Modern Update. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20246132"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107724","DOI":"10.1016\/j.exer.2019.107724","article-title":"Ocular mucins in dry eye disease","volume":"186","author":"Portal","year":"2019","journal-title":"Exp. Eye Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mencucci, R., Strazzabosco, G., Cristofori, V., Alogna, A., Bortolotti, D., Gaf\u00e0, R., Cennamo, M., Favuzza, E., Trapella, C., and Gentili, V. (2021). GlicoPro, Novel Standardized and Sterile Snail Mucus Extract for Multi-Modulative Ocular Formulations: New Perspective in Dry Eye Disease Management. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13122139"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Giannaccare, G., Ghelardini, C., Mancini, A., Scorcia, V., and Mannelli, L.D.C. (2021). New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease. J. Clin. Med., 11.","DOI":"10.3390\/jcm11010108"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1167\/iovs.10-6997f","article-title":"The international workshop on meibomian gland dysfunction: Report of the diagnosis subcommittee","volume":"52","author":"Tomlinson","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jtos.2023.04.010","article-title":"TFOS Lifestyle: Impact of contact lenses on the ocular surface","volume":"29","author":"Jones","year":"2023","journal-title":"Ocul. Surf."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101800","DOI":"10.1016\/j.clae.2022.101800","article-title":"A cross-sectional study of non-modifiable and modifiable risk factors of dry eye disease states","volume":"46","author":"Giraldez","year":"2023","journal-title":"Cont. Lens Anterior Eye"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jtos.2023.04.011","article-title":"TFOS Lifestyle: Impact of elective medications and procedures on the ocular surface","volume":"29","author":"Gomes","year":"2023","journal-title":"Ocul. Surf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/ICL.0000000000001001","article-title":"Intra-observer repeatability assessment of the S390L Firefly WDR slit lamp in patients with dry eye disease: Objective, automated and non-invasive measures","volume":"49","year":"2023","journal-title":"Eye Contact Lens"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.clae.2020.02.018","article-title":"Agreement and repeatability of four different devices to measure non-invasive tear breakup time (NIBUT)","volume":"43","author":"Bandlitz","year":"2020","journal-title":"Cont. Lens Anterior Eye"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/OPX.0000000000000472","article-title":"Ocular surface sensitivity repeatability with Cochet-Bonnet esthesiometer","volume":"92","author":"Chao","year":"2015","journal-title":"Optom. Vis. Sci."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0197-2456(02)00320-3","article-title":"Patient compliance with paper and electronic diaries","volume":"24","author":"Stone","year":"2003","journal-title":"Control Clin. Trials"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1475-1313.2010.00815.x","article-title":"Statistical guidelines for clinical studies of human vision","volume":"31","author":"Armstrong","year":"2011","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/opo.12009","article-title":"Statistical guidelines for the analysis of data obtained from one or both eyes","volume":"33","author":"Armstrong","year":"2013","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/opo.12399","article-title":"Recommendations for analysis of repeated-measures designs: Testing and correcting for sphericity and use of manova and mixed model analysis","volume":"37","author":"Armstrong","year":"2017","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/opo.12131","article-title":"When to use the Bonferroni correction","volume":"34","author":"Armstrong","year":"2014","journal-title":"Ophthalmic Physiol. Opt."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","article-title":"Role of hyperosmolarity in the pathogenesis and management of dry eye disease: Proceedings of the OCEAN group meeting","volume":"11","author":"Baudouin","year":"2013","journal-title":"Ocul. Surf."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"key":"ref_32","first-page":"8642","article-title":"Dry eye disease treatment: The role of tear substitutes, their future, and an updated classification","volume":"24","author":"Barabino","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Labetoulle, M., Benitez-Del-castillo, J.M., Barabino, S., Vanrell, R.H., Daull, P., Garrigue, J.S., and Rolando, M. (2022). Artificial Tears: Biological Role of Their Ingredients in the Management of Dry Eye Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052434"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1167\/iovs.04-0251","article-title":"An in vivo confocal masked study on corneal epithelium and subbasal nerves in patients with dry eye","volume":"45","author":"Wasfy","year":"2004","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1167\/iovs.06-0127","article-title":"Relation between corneal innervation with confocal microscopy and corneal sensitivity with noncontact esthesiometry in patients with dry eye","volume":"48","author":"Acosta","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1167\/iovs.06-1129","article-title":"The cornea in Sjogren\u2019s syndrome: An in vivo confocal study","volume":"48","author":"Villani","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtos.2021.08.004","article-title":"Alterations in corneal nerves in different subtypes of dry eye disease: An in vivo confocal microscopy study","volume":"22","author":"Cox","year":"2021","journal-title":"Ocul. Surf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/ICO.0b013e3181acf68d","article-title":"Corneal and conjunctival sensitivity in patients with dry eye: The effect of topical cyclosporine therapy","volume":"29","author":"Toker","year":"2010","journal-title":"Cornea"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/ICO.0000000000002383","article-title":"Tear Opiorphin Levels in Ocular Pain Caused by Corneal Foreign Body","volume":"39","author":"Ozdogan","year":"2020","journal-title":"Cornea"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","article-title":"Detrimental effect of preservatives in eyedrops: Implications for the treatment of glaucoma","volume":"86","author":"Baudouin","year":"2008","journal-title":"Acta Ophthalmol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/ICO.0000000000000695","article-title":"Comparison of the Efficacy of Fluorometholone With and Without Benzalkonium Chloride in Ocular Surface Disease","volume":"35","author":"Kim","year":"2016","journal-title":"Cornea"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","article-title":"Quantitative analysis of conjunctival goblet cells after chronic application of topical drops","volume":"25","author":"Kahook","year":"2008","journal-title":"Adv. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000335984","article-title":"Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions","volume":"48","author":"Liang","year":"2012","journal-title":"Ophthalmic Res."},{"key":"ref_46","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley","year":"2009","journal-title":"Clin. Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur. J. Ophthalmol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jtos.2021.05.001","article-title":"Demographic and lifestyle risk factors of dry eye disease subtypes: A cross-sectional study","volume":"21","author":"Wolffsohn","year":"2021","journal-title":"Ocul. Surf."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"101409","DOI":"10.1016\/j.clae.2021.01.004","article-title":"Modifiable lifestyle risk factors for dry eye disease","volume":"44","author":"Wang","year":"2021","journal-title":"Cont. Lens Anterior Eye"},{"key":"ref_50","first-page":"1096","article-title":"Corneal staining after instillation of topical anesthetic (SSII)","volume":"29","author":"Josephson","year":"1988","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1618\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:12:20Z","timestamp":1760105540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/6\/1618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":50,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["jcm13061618"],"URL":"https:\/\/doi.org\/10.3390\/jcm13061618","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]}}}